INNATE PHARMA : Communiqué

Bruce_Lee

28 octobre 2025 •15:34

Degiro. Actualités, 13h13

Innate Pharma SA has released a corporate presentation outlining its current strategy and clinical pipeline. The company highlights its leadership team and emphasizes expertise in antibody engineering to develop next-generation antibody therapeutics targeting cancer. The pipeline features several differentiated assets, including late-stage candidates with near-term commercial potential. Key programs include Lacutamab, an anti-KIR3DL2 antibody advancing toward potential accelerated approval and Phase 3 initiation, as well as other clinical and research-stage assets. The presentation also details partnerships with global pharmaceutical companies, with over €3.0 billion in potential milestones and significant royalties on net sales. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on October 28, 2025, and is solely responsible for the information contained therein.

(C) Copyright 2025 - Public Technologies (PUBT)